inclusion criteria: 1. admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adults ≥18 years of age at time of enrollment. 5. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. 6. ongoing illness of any duration, and at least one of the following: * radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or * blood oxygen saturation (spo2) ≤94% on room air, or * requiring supplemental oxygen, or * requiring mechanical ventilation or ecmo. 7. women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. 8. agrees to not to participate in another interventional trial for the treatment of covid-19 through day 60. exception 1: participant may co-enroll in activ-4 (activ-4a and activ-4c). exception 2: participants in activ-2 who have been hospitalized may be enrolled in activ-1 as long as activ-2 study therapy has been discontinued. they will remain in activ-2 follow-up. exception 3: if participant is already participating in a covid-19 vaccine trial but develops covid-19 disease that requires hospitalization, participant is eligible for this study, assuming all other inclusion/exclusion criteria are met.

inclusion criteria: 1. admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adults ≥18 years of age at time of enrollment. 5. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. 6. ongoing illness of any duration, and at least one of the following: * radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or * blood oxygen saturation (spo2) ≤94% on room air, or * requiring supplemental oxygen, or * requiring mechanical ventilation or ecmo. 7. women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. 8. agrees to not to participate in another interventional trial for the treatment of covid-19 through day 60. exception 1: participant may co-enroll in activ-4 (activ-4a and activ-4c). exception 2: participants in activ-2 who have been hospitalized may be enrolled in activ-1 as long as activ-2 study therapy has been discontinued. they will remain in activ-2 follow-up. exception 3: if participant is already participating in a covid-19 vaccine trial but develops covid-19 disease that requires hospitalization, participant is eligible for this study, assuming all other inclusion/exclusion criteria are met.

inclusion criteria: admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. male or non-pregnant female adults ≥18 years of age at time of enrollment. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. ongoing illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or blood oxygen saturation (spo2) ≤94% on room air, or requiring supplemental oxygen, or requiring mechanical ventilation or ecmo. women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. agrees to not to participate in another interventional trial for the treatment of covid-19 through day 60. exception 1: participant may co-enroll in activ-4 (activ-4a and activ-4c). exception 2: participants in activ-2 who have been hospitalized may be enrolled in activ-1 as long as activ-2 study therapy has been discontinued. they will remain in activ-2 follow-up. exception 3: if participant is already participating in a covid-19 vaccine trial but develops covid-19 disease that requires hospitalization, participant is eligible for this study, assuming all other inclusion/exclusion criteria are met.

inclusion criteria: admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. male or non-pregnant female adults ≥18 years of age at time of enrollment. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. ongoing illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or blood oxygen saturation (spo2) ≤94% on room air, or requiring supplemental oxygen, or requiring mechanical ventilation or ecmo. women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. agrees to not to participate in another interventional trial for the treatment of covid-19 through day 60. exception 1: participant may co-enroll in activ-4 (activ-4a and activ-4c). exception 2: participants in activ-2 who have been hospitalized may be enrolled in activ-1 as long as activ-2 study therapy has been discontinued. they will remain in activ-2 follow-up. exception 3: if participant is already participating in a covid-19 vaccine trial but develops covid-19 disease that requires hospitalization, participant is eligible for this study, assuming all other inclusion/exclusion criteria are met.

inclusion criteria: 1. admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adults ≥18 years of age at time of enrollment. 5. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. 6. ongoing illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - blood oxygen saturation (spo2) ≤94% on room air, or - requiring supplemental oxygen, or - requiring mechanical ventilation or ecmo. 7. women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. 8. agrees to not to participate in another interventional trial for the treatment of covid-19 through day 60. exception 1: participant may co-enroll in activ-4 (activ-4a and activ-4c). exception 2: participants in activ-2 who have been hospitalized may be enrolled in activ-1 as long as activ-2 study therapy has been discontinued. they will remain in activ-2 follow-up. exception 3: if participant is already participating in a covid-19 vaccine trial but develops covid-19 disease that requires hospitalization, participant is eligible for this study, assuming all other inclusion/exclusion criteria are met.

inclusion criteria: 1. admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adults ≥18 years of age at time of enrollment. 5. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. 6. ongoing illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - blood oxygen saturation (spo2) ≤94% on room air, or - requiring supplemental oxygen, or - requiring mechanical ventilation or ecmo. 7. women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. 8. agrees to not to participate in another interventional trial for the treatment of covid-19 through day 60. exception 1: participant may co-enroll in activ-4 (activ-4a and activ-4c). exception 2: participants in activ-2 who have been hospitalized may be enrolled in activ-1 as long as activ-2 study therapy has been discontinued. they will remain in activ-2 follow-up. exception 3: if participant is already participating in a covid-19 vaccine trial but develops covid-19 disease that requires hospitalization, participant is eligible for this study, assuming all other inclusion/exclusion criteria are met.

inclusion criteria: 1. admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adults ≥18 years of age at time of enrollment. 5. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. 6. ongoing illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - blood oxygen saturation (spo2) ≤94% on room air, or - requiring supplemental oxygen, or - requiring mechanical ventilation or ecmo. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. 8. agrees to not participate in another intervention trial for the treatment of covid-19 through day 60.

inclusion criteria: 1. admitted to a hospital or awaiting admission in the ed with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adults ≥18 years of age at time of enrollment. 5. has laboratory-confirmed (within 14 days prior to enrollment) sars-cov-2 infection as determined by pcr or other commercial or public health assay in any specimen. 6. ongoing illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - blood oxygen saturation (spo2) ≤94% on room air, or - requiring supplemental oxygen, or - requiring mechanical ventilation or ecmo. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 60. 8. agrees to not participate in another intervention trial for the treatment of covid-19 through day 60.